ZENECA ACCOLATE REDUCES BETA-AGONIST USE BY 22% IN PHASE III TRIAL, SHOWS EFFICACY SIMILAR TO CROMOLYN SODIUM; SEROQUEL PIVOTAL TRIALS FINISHING IN 1995
Zeneca's leukotriene-receptor antagonist Accolate (zafirlukast) is associated with improvements in daytime asthma symptoms and reductions in nighttime awakenings, according to two Phase III studies presented at the American Academy of Allergy & Immunology annual meeting held Feb. 24-March 1 in New York City.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth